Detail akcie MABION online

Business Summary: Mabion SA is a Poland-based company engaged in the research and development of biotechnological and biopharmaceutical medicinal products. Mabion SA was founded by four pharmaceutical companies, including Celon Pharma Ltd, Polfarmex Co, Genexo Ltd and IBSS Biomed Co, as well as two companies focused on research and development in biotechnology field, including BioCentrum Ltd and Biotech Consulting Ltd. The Company specializes in the humanized monoclonal antibodies (mAbs) technology, a new generation of biotechnological drugs. It focuses on oncology drugs used to treat blood cancer, lymphomas and leukemias, rheumatoid arthrisis, as well as breast cancer. It operates its own Research and Development Center in the Special Economical Zone in Lodz, Poland.
Financial Summary: BRIEF: For the six months ended 30 June 2023, Mabion SA revenues decreased 8% to PLN75.6M. Net income increased from PLN12.6M to PLN31.7M. Revenues reflect Sales of Materials decrease of 97% to PLN856K, Leasing decrease of 31% to PLN2.3M. Net income reflects Other Operating Expense - Balancing valu decrease of 98% to PLN11K (expense), Interest Expense decrease of 95% to PLN32K (expense).